Combination targeted adjuvant therapy doubles relapse-free survival in stage III melanoma
LUGANO-MADRID, 11 September, 2017 - Combination targeted adjuvant therapy with dabrafenib and trametinib doubles relapse-free survival in patients with stage...
 
  
 





